William White
Rheumatology · San Antonio, TXNPI 1467425686
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.4%), speaking fees and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Hikma Pharmaceuticals USA at 48.5% of the total. Reporting peaked in 2022 at $8,383 and has fallen 71.1% since, to $2,419 in 2023.
Across 451 payments — averaging $36.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hikma Pharmaceuticals USA$8K
- AbbVie$2K
- Amgen$2K
- UCB, Inc.$766
- Novartis$694
- Johnson & Johnson$564
- plus $3K from 17 others
What the payments were for
- Speaking & faculty fees$8,00049%
- Food & beverage$8,48051%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hikma Pharmaceuticals USA | 4 | $8,000 |
| AbbVie(2 entities) | 68 | $1,812 |
| Amgen(2 entities) | 100 | $1,767 |
| UCB, Inc. | 29 | $766 |
| Novartis | 35 | $694 |
| Johnson & Johnson | 60 | $564 |
| GSK | 24 | $533 |
| Pfizer | 31 | $531 |
| E.r. Squibb & Sons, L.L.C. | 19 | $407 |
| Genentech USA, Inc. | 21 | $347 |
| Lilly USA, LLC | 19 | $326 |
| AstraZeneca(2 entities) | 13 | $220 |
| Organon | 6 | $106 |
| Octapharma USA, Inc. | 5 | $104 |
| Pacira Therapeutics, Inc. | 3 | $91 |
| Boehringer Ingelheim | 3 | $62 |
| Sanofi | 2 | $41 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| Cumberland Pharmaceuticals, Inc. | 2 | $28 |
| GRT US Holding, Inc. | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Fidia Pharma USA Inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,487 in reported general payments places this provider in the 75th percentile of 512 rheumatology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 29 | $489 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in San Antonio
- Pendleton WickershamSan Antonio$954K
- Thomas RennieSan Antonio$113K
- Kevin KempfSan Antonio$83K
- Alex DejesusSan Antonio$68K
- Jane AyalaSan Antonio$67K
- Pankhuri GuptaSan Antonio$58K
- Fernando SilvaSan Antonio$54K
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.